Skip to main content
. 2021 Dec 17;17(12):e981–e988. doi: 10.4244/EIJ-D-21-00263

Figure 1.

Figure 1.

Aspirin, P2Y12 inhibitor, and dual antiplatelet therapy use at different time points during the three-year follow-up. Usage rates of each agent based on the total number of patients alive and on-study at that specific timepoint (i.e., end of interval), and thus the rates are different from those in Supplementary Table 7. DAPT: dual antiplatelet therapy